A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations
Launched by MEDIMMUNE LLC · Apr 15, 2011
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
This is an observational study in adult male and female subjects with COPD to collect blood, endobronchial tissues and BAL to investigate the inflammatory genes/pathways associated with AECOPD at the time of exacerbation (ie, active disease) and at 6 weeks later (ie, stable disease).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Physician-diagnosed acute exacerbations of chronic obstructive pulmonary disease
- • Current or ex-smoker with a tobacco history of 15 or more pack years
- • Females of childbearing potential must use birth control for the duration of the study.
- Exclusion Criteria:
- • Evidence or history of clinically significant disease
- • Subjects with asthma
- • Subjects taking anti-leukotriene medications
About Medimmune Llc
MedImmune LLC, a subsidiary of AstraZeneca, is a global biotechnology company dedicated to the development of innovative therapeutics for the treatment of serious diseases. With a strong focus on biologics, MedImmune leverages advanced scientific research and cutting-edge technology to create novel solutions in areas such as oncology, respiratory diseases, and autoimmune disorders. Committed to improving patient outcomes, MedImmune collaborates with healthcare professionals and organizations worldwide to advance clinical trials and bring life-changing therapies to market. Through its rigorous scientific approach and dedication to excellence, MedImmune plays a pivotal role in transforming the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dublin, , Ireland
Patients applied
Trial Officials
Rene van der Merwe, MBChB, MFPM
Study Director
MedImmune Ltd
Prof. Connor Burke
Principal Investigator
BCF Diagnostics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials